ChipCare has developed a portable diagnostic platform designed to bring blood testing to hard-to-reach populations in low and middle-income countries. The platform's polyvalence (ability to detect multiple classes of tests), mobility and cost-effectiveness make it quite unique. We have a beta prototype and will soon enter analytical studies with regulatory approval projected for later this year. We expect to reach commercialization in mid-2017.